Fujifilm opens office in biotech hub to develop research relationships

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/svanhorn)
(Image: Getty/svanhorn)

Related tags: Fujifilm, Biotech companies, Biotech hub, Massachusetts, Pharmaceutical companies, Boston, MIT

Fujifilm Life Science Strategic Business Office will open a site in Cambridge, Massachusetts in an aim to further link up with the surrounding pharmaceutical and biotech community.

The opening of the Cambridge, Massachusetts office, near major academic and clinical research institutions, which Fujifilm has worked to establish relationships with in recent months, demonstrates its aim to tap into early stage biologic development.

Bruce Novich, scientific director and division president at corporate new business development at Fujifilm Holdings, said, “Over the past few years, Fujifilm has made significant investments in the life science business including sponsored research, licensing, business partnerships and acquisitions.”

In its dip into the area, Fujifilm Life Science teamed up with Harvard Medical School, through its Fujifilm Fellowship Fund, to support research into therapeutic innovation.

The company also established a relationship with Massachusetts Institute of Technology through its sponsorship of research at the Koch Institute for Integrative Cancer Research to fund studies in targeted nucleic acid medicine delivery using lipid nanoparticle technology.

Additionally, Lyndra Therapeutics a pharmaceutical company in the Cambridge area, saw an investment from Fujifilm to fund the company’s Series B Financing for Phase II clinical trials and the expansion of its Phase I pipeline.

“Our new location in Cambridge provides an ideal environment to foster collaborate and bring business and technology together,”​ said Novich.

Yutaka Yamaguchi, CEO of Fujifilm Irvine Scientific and the general manager of the new Cambridge office, explained that the primary goal is to connect, invest, and co-innovate in an aim to accelerate translational medicine, and improve patient care.

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us

Products

View more

Webinars